# Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001

> **NCT02868229** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 61 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** COR-001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02868229
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-12
- **Primary completion:** 2018-12-11
- **Final completion:** 2018-12-11
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2021-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02868229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02868229, "Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02868229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*